HERA
HERA BIG 1-01 Share This Post Herceptin® (trastuzumab) in treating women with human epidermal growth factor receptor (HER) 2-positive primary breast cancer What HERA (HERceptin
TRANSBIG
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group to promote collaboration in translational breast cancer research.
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group (BIG) to promote collaboration in translational breast cancer research. TRANSBIG’s main focus was an international clinical trial known as MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy), which is sponsored by the European Organisation for the Research and Treatment of Cancer (EORTC) (www.eortc.org) and enrolled more than 6693 women in 9 European countries.
TRANSBIG’s overall aim was to individualise treatment by rapidly “translating” the latest discoveries in cancer biology made by laboratory scientists into tools that doctors can use to help make decisions about the way to treat patients.
This is because a refinement in prognosis allows for better prediction of the outcome of treatment and can thereby reduce the proportion of women receiving chemotherapy. This would simultaneously avoid unnecessary exposure to toxicity and harmful long-term side effects. The cost of cancer care would decrease, as would the burden on European health care systems.
TRANSBIG’s goal was achieved through the MINDACT clinical trial, which showed that a 70-gene signature, commercially known as MammaPrint®, when used in addition to common clinical-pathological criteria, could identify patients who could be spared adjuvant chemotherapy.
TRANSBIG ran a major international clinical trial called MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) to test a 70-gene tool (MammaPrint®) to identify which women needed chemotherapy after surgery and which did not. More information can be found here.
39 partners in 21 countries include the European and Latin American leaders in cancer treatment, genomics, microarray technology, proteomics, bioinformatics and biostatistics. Other critical elements in the fight against breast cancer are integrated into the TRANSBIG consortium as well: a patient advocacy network and a federation of cancer societies.
Breast International Group (BIG-aisbl), Brussels | International (Coordinator) |
Institut Jules Bordet / Jules Bordet Instituut, Brussels | Belguim |
The Netherlands Cancer Institute, Amsterdam | Netherlands |
Istituto Europeo di Oncologia – European Institute of Oncology | Italy |
Karolinska Institute & Hospital, Stockholm | Sweden |
Southwest Wales Cancer Institute, Swansea | UK |
The European Organization for the Research and Treatment of Cancer (EORTC), Brussels | International |
University of Glasgow, Glasgow | UK |
Vienna General Hospital | Austria |
Chilean Cooperative Group for Oncologic Research (GOCCHI) | Chile |
The Bank of Cyprus Oncology Centre, Nicosia | Cyprus |
Dept of Oncology of the 1st Faculty of Medicine Charles University and General Teaching Hospital, Prague | Czech Republic |
Rigshopitalet, Copenhagen | Denmark |
Institut Gustave Roussy, Villejuif | France |
West German Study Group / Frauenklinik der Heinrich-Heine- Universitaet Duesseldorf | Germany |
Universitaetsfrauenklinik – Frankfurt | Germany |
Dept. of OB/GYN, Technical University of Munich | Germany |
Universitaetsklinikum Eppendorf Hamburg | Germany |
National and Kapodistrian University of Athens | Greece |
St Vincent’s Hospital, Dublin | Ireland |
Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | Italy |
Centre Hospitalier de Luxembourg | Luxembourg |
University Maastricht / GROW | Netherlands |
Dept of Oncology & Radiotherapy, Medical University of Gdansk, Gdansk | Poland |
Portuguese Institute of Oncology, Porto Centre, Porto | Portugal |
N. N. Blokhin Cancer Research Centre, Moscow | Russia |
Institute of Oncology Ljubljana | Slovenia |
Institute of Oncology of Southern Switzerland | Switzerland |
Marmara University Hospital, Istanbul | Turkey |
Federation of European Cancer Societies | International |
Europa Donna | International |
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP) | Portugal |
International Institute for Drug Development | Belgium |
GSF – Research Centre for Environment and Health | Germany |
Agendia | Netherlands |
Vall d’Hebron University Hospital | Spain |
Grupo Espanol de Estudio y Tratamiento deTumores Solidos | Spain |
Swiss Institute of Bioinformatics | Switzerland |
The Chancellor, Masters and Scholars of the University of Oxford | United Kingdom |
Start date: 01/03/04
End date: 28/02/11
The TRANSBIG project received funding from the European Union’s European Commission’s Framework Programme VI under grant agreement number 503426.
HERA BIG 1-01 Share This Post Herceptin® (trastuzumab) in treating women with human epidermal growth factor receptor (HER) 2-positive primary breast cancer What HERA (HERceptin
TREAT CTC BIG 1-12 Share This Post TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) What Why / Objectives
Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.
The Breast International Group is proud to adhereto the Code of Ethics of the VEF-AERF
Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.